MSLE Company Profile and Key Details

Satellos Bioscience Inc. Common Stock generated EPS of -$1.57 over the past year. Five-year average earnings growth is 5.62%. Wall Street analysts project EPS growth of 6.14% annually over the next five years. Satellos Bioscience Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 11.14%.

Short-term trend indicators are bearishly aligned (SMA20 2.4%, SMA50 31.94%, SMA200 79.75%). The stock’s 14-day RSI is 63.22 (firm momentum), while the ATR of 0.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.96% below its high and over 156.8% above its low. Average 10-day trading volume of 55.66 thousand shares is below the 3-month average of 68.42 thousand, indicating normal recent market interest.

Satellos Bioscience Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.20. This means the shares are trading above this model’s fair value.

Satellos Bioscience Inc. Common Stock (NASDAQ:MSLE) closed at $11.63 USD, gaining $0.49 (4.40%) from the previous close of $11.14. The stock is currently mid-range between its 52-week high and low $4.52 and $12.50. With a market capitalization of about $14.98 million, Satellos Bioscience Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 23.78 thousand shares, trading with heavier-than-usual volume. Headquartered in Toronto, ON, Satellos Bioscience Inc. Common Stock operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Francis Gleeson, the company employs approximately 14 people and listed since May 10, 2024. Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics.

Our AI price prediction model suggests that Satellos Bioscience Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.34%, with price expected at $11.59 by March 11, 2026, within a range of $11.39 to $11.79 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 26, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 175.84%, with price at $32.08 by February 25, 2027, within a range of $32.05 to $32.13.

currently trading near 52-week highs band. Valuation shows Satellos Bioscience Inc. Common Stock trading at a premium to the broader market with a P/E of -7.83. Our AI forecast model points to short-term weakness (-0.34% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (175.84% over one year), with expected trading ranges indicating moderate volatility.

Satellos Bioscience Inc. Common Stock trades at a P/E ratio of -7.83, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.81 trading at moderately above to book value. The P/FCF stands at -0.72, also above market averages.